A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, wherein said solid tumor cancer is prostate cancer (PCa), comprising: A. Providing at least one biological sample previously obtained from said individual at a first point in time; B. Providing at least one biological sample previously obtained from said individual at a second point in time; C. In said at least two biological samples, quantifying a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of said at least one biomarker presence or concentration between the first point in time and the second point in time; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis, wherein the predetermined cut-off value discriminates between (i) a highly variable presence or concentration of the at least one biomarker, which is not related to development of the predefined solid tumor cancer, and (ii) a less variable presence or concentration of the at least one biomarker, which is related to development of the predefined solid tumor cancer; wherein • the time period between the first point in time and the second point in time is in the range from 0.1% to 30% of a typical tumor volume doubling time of said predefined solid tumor cancer; • wherein the typical tumor doubling time of said predetermined solid tumor cancer is 24 months; and • the at least one biomarker determined is the same biomarker in each of the biological samples. A. Providing at least one biological sample previously obtained from said individual at a first point in time; B. Providing at least one biological sample previously obtained from said individual at a second point in time; C. In said at least two biological samples, quantifying a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of said at least one biomarker presence or concentration between the first point in time and the second point in time; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis, wherein the predetermined cut-off value discriminates between (i) a highly variable presence or concentration of the at least one biomarker, which is not related to development of the predefined solid tumor cancer, and (ii) a less variable presence or concentration of the at least one biomarker, which is related to development of the predefined solid tumor cancer; • the time period between the first point in time and the second point in time is in the range from 0.1% to 30% of a typical tumor volume doubling time of said predefined solid tumor cancer; • wherein the typical tumor doubling time of said predetermined solid tumor cancer is 24 months; and • the at least one biomarker determined is the same biomarker in each of the biological samples.